SSUR
vs
S&P 500
SSUR
S&P 500
Over the past 12 months, SSUR has underperformed S&P 500, delivering a return of 0% compared to the S&P 500's +20% growth.
Stocks Performance
SSUR vs S&P 500
Performance Gap
SSUR vs S&P 500
Performance By Year
SSUR vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
StatSure Diagnostic Systems Inc
Glance View
StatSure Diagnostic Systems, Inc. engages in the research, development, and market of diagnostic tests for the detection of Human Immunodeficiency Virus. The company is headquartered in Framingham, Massachusetts and currently employs 4 full-time employees. The company went IPO on 2001-06-21. The Company’s StatSure Diagnostic Systems, Inc.’s SURE CHECK HIV 1/ 2 and Clearview Complete HIV 1/ 2 tests are easy-to-perform, single-use diagnostic tests for the rapid, visual detection of antibodies to HIV 1 and HIV 2. The Company’s HIV 1/ 2 diagnostic test is manufactured in the United States by Chembio Diagnostics is sold in the United States to clinics, hospitals and physicians by Alere under the brand name Complete HIV 1/ 2. Since the Company has introduced HIV rapid test product, its annual sales have shown very rapid growth. The Company’s Barrel Test format which is easy to use, needs only 2.5ml of blood (a fingerprick) and is designed specifically for consumers will become the consumer test of choice.